The mTOR signaling pathway as a treatment target for intracranial neoplasms

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

(2014) Claudia Fumarola et al.   BIOCHEMICAL PHARMACOLOGY

In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways

(2014) Inderjit Daphu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

(2014) Marco Giovannini et al.   NEURO-ONCOLOGY

mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models

(2013) D. Pachow et al.   CLINICAL CANCER RESEARCH

Significance of Akt activation and AKT gene increases in soft tissue tumors

(2013) Yoh Dobashi et al.   HUMAN PATHOLOGY

RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

(2013) Prakash Chinnaiyan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities

(2013) Mariella Gruber Filbin et al.   NATURE MEDICINE

Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target

(2013) Marianne Hütt-Cabezas et al.   NEURO-ONCOLOGY

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas

(2013) Matthias A. Karajannis et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

(2013) D. A. Krueger et al.   NEUROLOGY

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

(2013) M. Weiler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Deconvoluting mTOR biology

(2012) Jason D. Weber et al.   CELL CYCLE

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

(2012) K. A. Margolin et al.   CLINICAL CANCER RESEARCH

Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner

(2012) A. Kaul et al.   GENES & DEVELOPMENT

Neurofibromatosis Type 1: Modeling CNS Dysfunction

(2012) D. H. Gutmann et al.   JOURNAL OF NEUROSCIENCE

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types

(2012) M. F. James et al.   MOLECULAR CANCER RESEARCH

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

(2012) E. Q. Lee et al.   NEURO-ONCOLOGY

Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney

(2011) Laura R. Pearce et al.   BIOCHEMICAL JOURNAL

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models

(2011) Hong Zhao et al.   BREAST CANCER RESEARCH AND TREATMENT

Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival

(2011) D. L. Masica et al.   CANCER RESEARCH

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

MAPK pathway activation in pilocytic astrocytoma

(2011) David T. W. Jones et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

(2011) Birgit Geoerger et al.   EUROPEAN JOURNAL OF CANCER

A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study

(2011) Warren P. Mason et al.   INVESTIGATIONAL NEW DRUGS

mTOR links oncogenic signaling to tumor cell metabolism

(2011) Jessica L. Yecies et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes

(2011) S. Banerjee et al.   MOLECULAR CANCER THERAPEUTICS

Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size

(2011) Abdelhafid Saci et al.   MOLECULAR CELL

DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy

(2011) Yongchao Zhao et al.   MOLECULAR CELL

mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR

(2011) Daming Gao et al.   MOLECULAR CELL

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Everolimus

(2011) Monique P. Curran   PEDIATRIC DRUGS

PTEN Signaling pathways in glioblastoma

(2010) Dimpy Koul   CANCER BIOLOGY & THERAPY

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

(2010) Yasemin Sancak et al.   CELL

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

(2010) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide

(2010) Won Jun Oh et al.   EMBO JOURNAL

Tuberous sclerosis complex: tumors and tumorigenesis

(2010) Julita Borkowska et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Jann N. Sarkaria et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Pathological classification and molecular genetics of meningiomas

(2010) Christian Mawrin et al.   JOURNAL OF NEURO-ONCOLOGY

mTORC1 activation in childhood ependymoma and response to sirolimus

(2010) Daniel C. Bowers et al.   JOURNAL OF NEURO-ONCOLOGY

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTORC1 signaling: what we still don't know

(2010) X. Wang et al.   Journal of Molecular Cell Biology

Duplication of 7q34 in Pediatric Low-Grade Astrocytomas Detected by High-Density Single-Nucleotide Polymorphism-Based Genotype Arrays Results in a NovelBRAFFusion Gene

(2009) Angela J. Sievert et al.   BRAIN PATHOLOGY

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents

(2009) Terence O’Reilly et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms

(2009) E.A. Dunlop et al.   CELLULAR SIGNALLING

mTOR signaling at a glance

(2009) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas

(2009) Tim Forshew et al.   JOURNAL OF PATHOLOGY

NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth

(2009) M. F. James et al.   MOLECULAR AND CELLULAR BIOLOGY

ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery

(2009) Chang Hwa Jung et al.   MOLECULAR BIOLOGY OF THE CELL

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma

(2009) Renee D. Read et al.   PLoS Genetics

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma

(2008) B. Hegedus et al.   CANCER RESEARCH

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

(2008) Tsuneo Ikenoue et al.   EMBO JOURNAL

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

(2008) Valeria Facchinetti et al.   EMBO JOURNAL

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

(2008) James Rubenstein et al.   LEUKEMIA & LYMPHOMA

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Regulation of TORC1 by Rag GTPases in nutrient response

(2008) Eunjung Kim et al.   NATURE CELL BIOLOGY

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

(2008) Beth Apsel et al.   Nature Chemical Biology

Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome

(2008) M S Orloff et al.   ONCOGENE

PTEN: a new guardian of the genome

(2008) Y Yin et al.   ONCOGENE

mTOR—What Does It Do?

(2008) M.N. Hall   TRANSPLANTATION PROCEEDINGS

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE

mTOR Is Activated in the Majority of Malignant Melanomas

(2007) Magdalena Karbowniczek et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY